Xiaobing Chen

机构：Zhengzhou University, Henan Cancer Hospital, Huai'an University · ORCID：0000-0002-9708-7821

发表论文 91 篇 · 总被引 2121 次 · h-index 27

代表论文

• Application and synthesis of thiazole ring in clinically approved drugs (2023 · European Journal of Medicinal Chemistry · 被引 180)
• Structure-Based Design, Synthesis, and Biological Evaluation of New Triazolo[1,5- a ]Pyrimidine Derivatives as Highly Potent and Orally Active ABCB1 Modulators (2020 · Journal of Medicinal Chemistry · 被引 48)
• First-line camrelizumab (a PD-1 inhibitor) plus apatinib (an VEGFR-2 inhibitor) and chemotherapy for advanced gastric cancer (SPACE): a phase 1 study (2024 · Signal Transduction and Targeted Therapy · 被引 44)
• Degraders in epigenetic therapy: PROTACs and beyond (2024 · Theranostics · 被引 39)
• Discovery of the Triazolo[1,5-a]Pyrimidine-Based Derivative WS-898 as a Highly Efficacious and Orally Bioavailable ABCB1 Inhibitor Capable of Overcoming Multidrug Resistance (2021 · Journal of Medicinal Chemistry · 被引 32)
• Multiomics-based molecular subtyping based on the commensal microbiome predicts molecular characteristics and the therapeutic response in breast cancer (2024 · Molecular Cancer · 被引 29)